GDF11
Growth Differentiation Factor 11
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
The signature anti-aging claims for GDF11 are contested and were substantially contradicted. The original Harvard reports (Loffredo 2013 Cell on cardiac hypertrophy, Sinha 2014 Science on skeletal muscle, Katsimpardi 2014 Science on neurogenesis) rested on an assay whose antibody was later shown to cross-react with myostatin, and the Novartis-led rebuttal (Egerman 2015 Cell Metabolism) reported that circulating GDF11 actually rises with age and impairs rather than restores muscle regeneration. There are no controlled human trials of GDF11 administration, so any rejuvenation use remains animal-and-in-vitro only with directly conflicting results, which places it at grade 1.
- FDA
- No FDA approval and no human administration trials of GDF11 itself; investigational research target only
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Not an approved therapy or supplement; rejuvenation claims are contested and were contradicted, and exogenous GDF11 has been reported to impair muscle regeneration and cause cardiac and skeletal muscle wasting in animal work.
Talk to a clinician before taking this, particularly if you have a heart condition. The Atlas can tell you what has been studied about GDF11. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
A circulating TGF-beta family protein at the center of the "young blood" parabiosis controversy. Early studies suggested it rejuvenated aged tissue; later work disputed the findings. One of the most scientifically contested longevity factors.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
GDF11 is a circulating protein in the TGF-beta family that sits at the center of a famous theory of aging. The theory came from parabiosis experiments, in which a young and an old animal are surgically joined to share one blood supply, and the old animal’s tissues appear to grow younger. Researchers proposed that GDF11 is a rejuvenation factor carried in young blood, one that declines with age, and that restoring it reverses aging in the heart, muscle and brain, shrinking age-related heart enlargement, restoring muscle stem cells and boosting brain cell formation. The trouble is that the science behind this is genuinely contested.
GDF11 is a TGF-beta-superfamily protein, a disulfide-linked dimer cut from a larger precursor. The single most important structural fact about it is that it is roughly 90% identical in sequence to myostatin, the muscle-limiting factor also called GDF8. That near-twin resemblance turned out to be central to the entire controversy, because the tools used to measure GDF11 could not reliably tell the two apart. Recombinant GDF11 exists as a research protein.
- Type
- TGF-beta-family protein
- Resembles
- Myostatin (~90%)
- Claimed role
- Rejuvenation factor
- Status
- Contested, preclinical
- Human trials
- None
- Approved
- No
The "Young Blood" Factor, Disputed
GDF11 became famous around 2013 and 2014, when high-profile Harvard studies using young-old shared-circulation experiments identified it as a young-blood rejuvenation factor that declines with age and reverses aging of the heart, muscle and brain, and the media ran with it. But independent groups could not replicate the core findings, and the problems were fundamental. The original measurements could not reliably distinguish GDF11 from its near-twin myostatin, so the claim that it declines with age is unreliable, and several studies found it does not decline, and may even rise with age while tracking with frailty. Worse, some independent work found GDF11 inhibits muscle regeneration, the opposite of rejuvenation, and that higher levels may worsen heart injury. The biology is genuinely complex and dose-dependent, so it is contested rather than settled either way, but the dramatic anti-aging narrative did not survive independent scrutiny.
Safety in detail
GDF11 is a secreted signaling protein studied in animals and cell models, not a validated human treatment. Independent studies associate exogenous GDF11 with impaired muscle regeneration and with cardiac and skeletal muscle wasting, so the safety of any administration in people is unestablished.
- There is no human safety data, because GDF11 has not been tested as a therapy in human trials.
- The contested biology means even the direction of effect is unclear, with some evidence pointing to harm rather than benefit.
- Independent work suggests it can inhibit muscle regeneration, that higher levels may worsen heart injury, and that elevated levels track with frailty, the opposite of the marketing.
- It is not approved, and gray-market recombinant product carries authenticity risks, compounded by the difficulty of even distinguishing it from myostatin.
- Manipulating a developmental TGF-beta factor with unclear net effects is inherently risky.
Children and teenagers
GDF11 is a contested TGF-beta factor with unclear and possibly harmful effects, and has no place in anyone under 18. Although it is biologically important in development, manipulating it is not a pediatric therapy, and there is no data or rationale for such use. There is no appropriate pediatric use.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
GDF11 has no approved product; the early pharmaceutical and patent interest, including for heart failure, never became a drug. Its market is gray: recombinant-peptide vendors selling GDF11 and longevity and anti-aging clinics offering it, riding the young-blood and rejuvenation narrative. The selling point is the celebrated original story, while the failure of independent replication and the evidence of possible harm go unmentioned.
How we got here
GDF11 was first identified in the 1990s as a bone morphogenetic protein and carried the name BMP-11 before being reclassified as Growth Differentiation Factor 11 within the TGF-beta superfamily, where it sits as the near-twin of myostatin (GDF8). It entered popular attention through the 2013 to 2014 Harvard parabiosis work led by Amy Wagers and colleagues, which cast it as a circulating young-blood factor that declined with age and rejuvenated heart, muscle, and brain, and it was folded into Science magazine's 2014 breakthrough coverage. That story was substantially disputed beginning in 2015, when a Novartis-led group (Egerman et al.) reported that the antibody underpinning the original measurements cross-reacted with the far more abundant myostatin, that GDF11 in fact rises rather than falls with age, and that it impairs muscle regeneration. It has never been an approved drug or a consumer supplement; it circulates today as a research reagent (recombinant GDF11) and as an investigational target pursued by biotech such as Elevian, and it is catalogued in this library under the id gdf11.
GDF11 was first identified as a developmental factor, then leapt to fame around 2013 and 2014 when the Lee, Wagers and Rubin laboratories used young-old shared-circulation experiments to crown it a young-blood rejuvenation factor that reverses aging of the heart, muscle and brain. The claims drew enormous media attention. But beginning in 2015, independent groups, including at Novartis, could not replicate the findings, showed the original assays could not distinguish GDF11 from myostatin, and found GDF11 could inhibit muscle regeneration. Later work suggested its levels do not fall with age and may track with frailty and worse cardiac outcomes. Despite this, recombinant GDF11 spread through gray-market longevity channels on the strength of the original hype.
- 2013A Cell study reports GDF11 reverses age-related heart enlargement in mice.
- 2014Science studies report muscle and brain rejuvenation, making GDF11 a young-blood sensation.
- 2015Independent groups fail to replicate the findings and expose the assay confusion with myostatin.
- 2010s-2020sStudies suggest GDF11 does not decline with age and may track with frailty and worse heart outcomes.
- 2010s-2020sRecombinant GDF11 persists gray-market as an anti-aging peptide on the original hype.
The numbers behind the grade
- Type
- TGF-beta protein
- Resembles
- Myostatin (~90%)
- Claim
- Reverses aging (disputed)
- Replication
- Failed independently
- Human trials
- None
- Approved
- No
The people taking it
Famous as the young-blood anti-aging rejuvenation factor and one of the most-hyped longevity molecules of the 2010s, but with dramatic claims that are scientifically disputed and partly reversed.
GDF11’s users are longevity-focused: anti-aging biohackers drawn to the young-blood and rejuvenation story, people worried about cardiac, muscle or cognitive aging, and the broader reverse-aging crowd, often affluent self-experimenters. The appeal is the celebrated original narrative rather than the contested and sometimes contradictory science that followed.
Used gray-market as an anti-aging and rejuvenation peptide on the young-blood narrative, with no human data and contested, sometimes contradictory science. Not approved.
Set against the alternatives
The unavoidable comparison is to myostatin, GDF11’s near-twin, which they resemble so closely that measurement tools confused them, and which limits muscle growth, raising the possibility that GDF11 shares that muscle-inhibiting behavior rather than rejuvenating. Against the young-blood and parabiosis idea more broadly, the rejuvenating effect of young circulation may be real, but GDF11’s specific role as the cause is what fell apart. And against Follistatin, which builds muscle by blocking myostatin and GDF11, the contrast is sharp: that muscle-building effect is far better supported than GDF11’s disputed rejuvenation claim. Its strength was a captivating hypothesis; its weakness is that independent science did not confirm it.
What we do not know
- Whether GDF11 has any genuine rejuvenating effect, or the opposite.
- Whether its levels actually decline with age, rise, or stay flat.
- How it can even be measured reliably given its near-identity to myostatin.
- Whether any of the original parabiosis-driven claims survive independent testing.
What could change
Unresolved biologyIts true, likely context- and dose-dependent effects remain genuinely unsettled.Cautionary-tale statusGDF11 is now a textbook example of an exciting claim that independent science could not confirm.Cautious researchWork continues, but with far more skepticism than the original excitement.Persistent gray marketAnti-aging sales continue despite the contested evidence.
Legal status
GDF11 is not approved and has no human trials; it is a preclinical, contested research protein. It is sold gray-market as a recombinant anti-aging peptide, which is not an approved use. It is not a classic anti-doping substance, but its unapproved, contested status and possible harms argue against use.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Available only as gray-market recombinant research material, which is not for human use, has no safety or efficacy data, and rests on disputed science with some evidence of harm. There is no legitimate route, and the honest guidance is caution: the rejuvenation claims are contested and parts of the evidence point the opposite way.
Gray-market recombinant GDF11 is moderately to expensively priced, as recombinant proteins tend to be, but the cost buys an unproven and contested material whose authenticity is hard to verify. There is no validated product to price against.
Produced recombinantly overseas, predominantly in China, and sold as research material with no quality assurance and real identity concerns given its near-identity to myostatin. A certificate of analysis is the only check and is especially weak here.
China and research vendorsThe dominant source of recombinant GDF11, sold gray-market as an anti-aging material.Identity concernsAs a recombinant protein nearly identical to myostatin, its purity and even its identity are hard to verify.Clinic channelSome longevity clinics offer it off-label on the strength of the original hype.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about GDF11.
Nothing outstanding on this one.
Sources
Original Harvard claim that GDF11 is a circulating young-blood factor that reverses age-related cardiac hypertrophy in mice
Novartis rebuttal: circulating GDF11 increases with age and inhibits skeletal muscle regeneration, opposite to the original claims
The anti-GDF11 antibody used in the field cross-reacts with myostatin (GDF8), meaning the measured age-related decline was likely myostatin, not GDF11
Follow-up human quantification of GDF11 and myostatin in aging and cardiovascular disease using a specific assay
Independent report that exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting, contradicting a rejuvenation role
Science journalism documenting that doubts were cast on the rejuvenating-protein claim and that the antibody specificity was in question
Coverage that the young-blood anti-aging mechanism attributed to GDF11 was called into question
Researcher-facing review noting there are no reports of GDF11 administration in humans, no FDA approval, and unresolved safety concerns
Alzheimer's Drug Discovery Foundation, Cognitive Vitality GDF-11 report
Review of GDF11 and myostatin biochemistry and biology detailing their similarities, differences, and shared-assay problems
The studies that matter
Loffredo et al, Cell2013
Reported that GDF11 declines with age and that restoring it reverses age-related heart enlargement in mice, the founding cardiac claim.
Sinha and Katsimpardi et al, Science2014
Reported that GDF11 rejuvenates aged skeletal muscle and the aging brain, the studies that made it a young-blood sensation.
Independent challenge2015
Other groups, unable to replicate the findings, showed the original assays were not GDF11-specific and that GDF11 can inhibit muscle regeneration.
Age and frailty studies2010s-2020s
Several studies found GDF11 does not decline with age, and may rise, with higher levels linked to frailty and adverse outcomes in elderly patients.
Human cardiac association2020s
Circulating GDF11 was associated with larger heart-attack injury in humans, contradicting the protective, rejuvenating picture.